电邮这篇文章 Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform
- 期: 卷 23, 编号 1 (2021)
- 页面: 45-47
- 栏目: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/70288
- DOI: https://doi.org/10.26442/18151434.2021.1.200707
- ID: 70288
如何引用文章
全文:
详细
In 2020, within the framework of the educational project Talisman on BRCA-associated HER2-negative metastatic breast cancer (mBC), Pfizer with the support of TS Oncology held 4 educational and discussion events based on the OncoForum platform (virtual-platform developed and operated by TS Oncology). 44 key specialists from federal and regional cancer centers representing 7 federal districts took part in these events and shared their opinion on the current state of availability of molecular genetic research for germline mutations in BRCA genes and treatment approaches of BRCA-associated HER2-negative mBC in Russia. The results of these interactive discussions are represented in the current overview.
参考
- Keung MYT, Wu Y, Vadgama JV, et al. PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. J Clin Med 2019; 8: 435. doi: 10.3390/jcm8040435
- Poggio F, Bruzzone M, Ceppi M, et al. Single-agent PARP inhibitors for the treatment of patients with BRCA mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. ESMO Open 2018; 3: e000361. doi: 10.1136/esmoopen-2018-000361
- Постановление Правительства РФ от 28.12.2020 №2299 «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2021 год и на плановый период 2022 и 2023 годов» [Postanovlenie Pravitel’stva RF ot 28.12.2020 №2299 “O Programme gosudarstvennykh garantii besplatnogo okazaniia grazhdanam meditsinskoi pomoshchi na 2021 god i na planovyi period 2022 i 2023 godov” (in Russian)].
- Постановление Правительства РФ от 07.12.2019 №1610 «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2020 год и на плановый период 2021 и 2022 годов» [Postanovlenie Pravitel’stva RF ot 07.12.2019 №1610 “O Programme gosudarstvennykh garantii besplatnogo okazaniia grazhdanam meditsinskoi pomoshchi na 2020 god i na planovyi period 2021 i 2022 godov” (in Russian)].
- Клинические рекомендации Минздрава России. Рак молочной железы. 2021 (КР379). Режим доступа: http://cr.rosminzdrav.ru/clin_recomend [Klinicheskie rekomendatsii Minzdrava Rossii. Rak molochnoi zhelezy. 2021 (KR379). Available at: http://cr.rosminzdrav.ru/clin_recomend (in Russian)].
- Рекомендации Российского Общества онкомаммологов. «Золотой стандарт» диагностики и лечения рака молочной железы 2021, версия 2.0. Режим доступа: http://www.abvpress.ru/project/www.abvpress.ru/ KR_ROOM_2021_Zolotoy_standart_NEW.pdf [Rekomendatsii Rossiiskogo Obshchestva onkomammologov. “Zolotoi standart” diagnostiki i lecheniia raka molochnoi zhelezy 2021, versiia 2.0. Available at: http://www.abvpress.ru/project/www.abvpress.ru/KR_ROOM_2021_Zolotoy_standart_NEW.pdf (in Russian)].
- Стенина М. Б., и др. Практические рекомендации по лекарственному лечению рака молочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2019; 9. Режим доступа: https://rosoncoweb.ru/standarts/RUSSCO/2019/2019-08.pdf [Stenina M B, et al. Prakticheskie rekomendatsii po lekarstvennomu lecheniiu raka molochnoi zhelezy. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO #3s2. 2019; 9. Available at: https://rosoncoweb.ru/standarts/RUSSCO/2019/2019-08.pdf (in Russian)].
- Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. NEJM 2018; 379 (8): 753–63.
- Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019; 30: 558–66.
- Hennes ER, Dow-Hillgartner EN, Bergsbaken JJ, Piccolo JK, et al. PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost. J Oncol Pharm Practice 2020; 1–12.
- Available at: https://clinicaltrials.gov/ct2/results?term=talazoparib
